DrugChEMBL
Bisantrene
Bisantrene is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
-
Type
DRUG
Molecule
Small molecule
Registry-listed formulations
bisantrene · mesh:C031404
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
0 source entries across 0 studies. This list may not include all unresolved or historical entries.
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Phase 2
2
100%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Other(1)
Detailed Status
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
unknown150%
completed150%
Recent Activity
Clinical Trials (2)
Showing 2 of 2 trials
NCT04989335Phase 2
Bisantrene Combination for Resistant AML
NCT03820908Phase 2
Bisantrene for Relapsed /Refractory AML
All 2 trials loaded
Drug Details
- Intervention Type
- Drug
- Molecule Type
- Small molecule
- Total Trials
- 2
External References
ChEMBL
CHEMBL25336Names & Codes
Research Codes
CL 216942NSC 337766